Oncotarget
HER3: A Vital Target in Cancer Treatment
Oct 12, 2023
Dr. Omkar Desai discusses the significance of HER3 in promoting cancer cell growth and chemo resistance. Challenges in translating preclinical studies on HER3 targeted therapies to clinical trials and HER3 overactivation as a resistance mechanism in cancer cells are explored. Emphasizing the importance of identifying HER3 expression and gene fusions as predictive biomarkers and developing combination therapies to combat resistance.
08:49
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- HER3 is a major driver of cancer cell proliferation and chemo resistance in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.
- HER3 expression can serve as a predictive biomarker for patient response to HER3 targeted therapies in metastatic pancreatic ductal adenocarcinoma.
Deep dives
HER3 as a significant factor in colorectal cancer and pancreatic ductal adenocarcinoma
Recent research has identified HER3 as a significant factor contributing to cancer cell proliferation and chemo resistance in metastatic colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PEDAC). HER3 is activated by hepatocytes in the liver, leading to cancer cell proliferation through survival pathways such as AKT. Inhibiting HER3 effectively suppresses tumor growth in models and may be useful in treating patients with both K-RAS wild-type or mutant metastatic CRC either alone or in combination with standard therapies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
